Vu Nguyen Ngo

Vu Nguyen Ngo, Ph.D.

  • Associate Research Professor, Department of Systems Biology

Vu Nguyen Ngo, Ph.D.

Research Focus :
  • Molecular pathogenesis of lymphoid malignancies
Cancer cells are often addicted to a transformed state that involves multiple signal transduction pathways. A major goal of Dr. Ngo’s research is to discover abnormal signaling that make cancer more aggressive and resistant to therapy. By combining high throughput genetic screen and next-generation sequencing approaches, he has identified key pathways and important molecular targets that are critical for cancer cell proliferation and survival (Ngo VN et al. 2011, Nature). His research has also led to discovery of cancer gene mutations that cause treatment resistance (Mohanty A et al. 2016, Oncotarget).

Dr. Ngo’s laboratory in the Department of Systems Biology will focus on genetic and epigenetic mechanisms of cancer mutations and their interactions in driving tumor development. His laboratory will employ large-scale functional genetic screens using RNA interference technology in combination with genomics and proteomics approaches to dissect disease mechanisms in lymphoid malignancies. He also has a special focus on developing animal tumor models for aggressive lymphomas including mantle cell lymphoma.

Dr. Ngo completed his B.A. degree from the University of California, Berkeley and earned a Ph.D. in biomedical sciences from the University of California, San Francisco. His postdoctoral training was with Dr. Louis M. Staudt at the National Cancer Institute, National Institute of Health, Bethesda. Prior to joining the Department of Systems Biology, he was an assistant professor in the Division of Stem Cell and Leukemia Research at City of Hope. He has received the American Society of Hematology Scholar Award, Gabrielle’s Angel Foundation for Cancer Research Award and Department of Defense’s Career Development Award.
  • 2017 - present, Associate Research Professor, Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA
  • 2010 - present, Member, Irell & Manella Graduate School of Biological Sciences, City of Hope, Duarte, California
  • 2010 - present, Member, City of Hope's Comprehensive Cancer Center, Duarte, California
  • 2010 - 2017, Assistant Professor, Beckman Research Institute of City of Hope, Duarte, California
  • 2007 - 2010, Staff Scientist, National Cancer Institute, National Institute of Health, Bethesda, Maryland
  • 2006 - 2007, Research Fellow, National Cancer Institute, National Institute of Health, Bethesda, Maryland
  • 1998, Teaching Assistant, Department of Anatomy, University of California San Francisco, San Francisco, California
  • 1994 - 1996, Research Technician, California Institute of Technology, Pasadena, California
  • Department of Systems Biology

Degrees

  • 1996 - 2001, Ph.D. Biomedical Sciences, Thesis Advisor: Dr. Jason G. Cyster, University of California San Francisco, San Francisco, California
  • 1992 - 1994, B.A. Molecular Cell Biology, Research Mentor: Dr. Astar Winoto, University of California Berkeley, Berkeley, California

Fellowship

  • 2001 - 2006, Postdoctoral fellow in the laboratory of Dr. Louis M. Staudt, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
The research program in the Ngo laboratory is focused on pathogenetic mechanisms of lymphoid malignancies. Through a combination of high-throughput functional genetic screen and animal modeling approaches, the Ngo laboratory aims to discover abnormal signal transduction pathways and identify novel molecular targets in aggressive lymphomas. In 2010, Dr. Ngo was recruited to start his independent laboratory in the division of Stem Cell and Leukemia Research at the Beckman Research Institute at City of Hope. His laboratory has discovered an important role for recurrent mutations of cyclin D1, which results in deregulated protein turnover and therapy resistance in mantle cell lymphoma. In 2017, Dr. Ngo joined the Department of Systems Biology where he will use innovative functional genomics tools and powerful animal modeling using relevant patient-derived lymphoma samples to gain new insights into critical signaling pathways that are important in lymphomagenesis and treatment resistance.
  • Mohanty S, Mohanty A, Sandoval N, Tran T, Bedell V, Wu J, Scuto A, Murata-Collins J, Weisenburger DD, Ngo VN. Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leukemia & Lymphoma. 2017; 58(3): 676-688.
  • Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016; 7(45):73558-73572.
  • Ngo VN. Identification of pathogenetically relevant genes in lymphomagenesis by shRNA library screens. Methods Mol Biol. 2013; 971:245-63.
  • Ngo VN, Young R, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically Active MYD88 Mutations in Human Lymphoma. Nature. 2011; 470 (7332): 115-9.
  • Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, et al.  A Loss-of-function RNA Interference Screen for Molecular Targets in Cancer. Nature. 2006; 441 (7089): 106-10.
     

View all publications

  • 2014, City of Hope Excellence Research Award
  • 2014-2017, Gabrielle’s Angel Foundation for Cancer Research Award
  • 2013-2015, Stop Cancer Career Development Award
  • 2012-2015, American Society of Hematology Scholar Award
  • 2012, Stop Cancer Rosalinde and Arthur Gilbert Foundation Seed Grant
  • 2012, Margaret E. Early Medical Research Trust Award
  • 2011-2014, Tim Nesvig Lymphoma Fellowship
  • 2004-2006, National Institutes of Health Cancer Research Training Award
  • 2001-2004, Damon Runyon Cancer Research Postdoctoral Fellowship
Back To Top